Our products are not intended to treat, prevent, mitigate or cure any disease or medical condition and are for research purposes only.
since GLP-1s often lead to weight loss, this may be the primary reason women notice a "cooling" effect on their vasomotor symptoms
Ryan GJ, Foster KT, Jobe LJ
Consequently, companies such as Novo Nordisk and Eli Lilly are investing heavily in next-generation formulations, including oral small-molecule GLP-1 receptor agonists such as orforglipron, which aim to expand patient accessibility and therapeutic scope The demand for GLP-1 drugs that address a wider array of metabolic conditions is growing rapidly across global markets, as patients and healthcare providers increasingly seek holistic and effective long-term treatment options for obesity and its comorbidities GLP-1 Receptor Agonists Obesity Drugs Market Dynamics Driver Surging Demand Due to Rising Obesity Prevalence and Enhanced Clinical Outcomes The global surge in obesity rates and associated comorbidities such as type 2 diabetes and cardiovascular diseases is significantly driving demand for GLP-1 receptor agonist drugs as effective medical weight loss therapies For instance, in May 2024, Novo Nordisk announced a USD 4.1 billion expansion in its U.S
Keep out of reach of small children
Designed as a powerful dietary supplement, this advanced antioxidant blend combines L-Glutathione, Vitamin C, Vitamin E, and Alpha Lipoic Acid (ALA) to help promote a smoother, brighter, and more youthful complexion
